Status:
UNKNOWN
CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Lead Sponsor:
Peking University
Conditions:
Triple-negative Breast Cancer
HER2-positive Breast Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
This is a prospective, single-center, non-randomized, non-controlled observational study.
Detailed Description
Almost 55-62% of patients with triple-negative or human epidermal growth factor receptor 2 (HER2) positive, node-positive breast cancer achieve an axillary pathologic complete remission (pCR) after ne...
Eligibility Criteria
Inclusion
- Triple-negative or HER2-positve invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration or core needle biopsy.
- Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy.
- Attend the study voluntarily, sign the informed consent.
Exclusion
- Contradiction for adjuvant chemotherapy.
- Contradiction for proceeding surgery.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT04457700
Start Date
November 1 2020
End Date
December 30 2022
Last Update
April 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142